Insmed Incorporated (BMV:INSM)
| Market Cap | 595.79B -25.2% |
| Revenue (ttm) | 27.39B +240.0% |
| Net Income | -10.92B |
| EPS | -53.72 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 547 |
| Open | 2,752.00 |
| Previous Close | 2,230.00 |
| Day's Range | 2,752.00 - 2,760.00 |
| 52-Week Range | 1,690.00 - 3,760.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Insmed
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 ... [Read more]
Financial Performance
In 2025, Insmed's revenue was $606.42 million, an increase of 66.73% compared to the previous year's $363.71 million. Losses were -$1.28 billion, 39.7% more than in 2024.
Financial numbers in USD Financial StatementsNews
Insmed deal makes ‘considerable strategic sense’ for Sanofi, says BMO Capital
After Bloomberg reported that Sanofi (SNY) is evaluating a potential acquisition of Insmed (INSM), BMO Capital analyst Conor MacKay argued that adding Insmed’s differentiated respiratory growth engine...
30% premium for Insmed ‘not out of reach’ for Sanofi, says Jefferies
Jefferies notes Bloomberg reported that Sanofi (SNY) is considering acquiring Insmed (INSM), which is currently valued at about $27B. Given that Sanofi’s CFO has suggested that large acquisitions are ...
Insmed’s strategic value in focus amid rumored Sanofi bid, says Raymond James
Raymond James reiterates an Outperform rating on Insmed (INSM) shares. Sanofi (SNY) is reportedly exploring an acquisition of Insmed, though discussions remain preliminary with no formal offer, reinfo...
Mizuho doesn’t believe Insmed ready to sell
Mizuho analyst Graig Suvannavejh notes Insmed (INSM) shares were up as much as 20% intraday following Bloomberg’s report that Sanofi (SNY) is weighing an acquisition of the company. Insmed has…
Insmed Stock Already Was Flying High. Sanofi Takeover Buzz Lights the Afterburners.
Insmed stock jumps following a report saying Sanofi is eyeing a takeover of the biopharma company.
Insmed trading halted, volatility trading pause
10:05 EST Insmed (INSM) trading halted, volatility trading pause
Sanofi considering takeover of Insmed, Bloomberg reports
10:06 EST Sanofi (SNY) considering takeover of Insmed (INSM), Bloomberg reports
Insmed jumps 8% after Bloomberg report on Sanofi takeover interest
10:07 EST Insmed (INSM) jumps 8% after Bloomberg report on Sanofi (SNY) takeover interest
Sanofi eyeing takeover of U.S. drugmaker Insmed, Bloomberg reports
Sanofi (SNY) is exploring a potential acquisition of U.S. drugmaker Insmed (INSM), which could rank among the largest biopharma deals in recent years, Bloomberg’s Michelle F. Davis, David Carnevali, R...
Insmed Transcript: Jefferies Global Healthcare Conference
BRINSUPRI’s 2026 launch is tracking to $1.35B-$1.4B, with low penetration and strong persistence supporting further growth. 2027 catalysts include DTC, Japan expansion, frontline ARIKAYCE launches and pipeline milestones; cash-flow positivity is expected.
Insmed to Present at November and December 2026 Investor Conferences
BRIDGEWATER, N.J., Nov. 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform ...
Insmed assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Matthew Caufield assumed coverage of Insmed (INSM) with a Buy rating and $220 price target The firm says Brinsupri is the first and only FDA-approved therapy for…
Insmed price target raised to $158 from $154 at Mizuho
Mizuho raised the firm’s price target on Insmed (INSM) to $158 from $154 and keeps an Outperform rating on the shares.
Insmed price target lowered to $201 from $205 at Guggenheim
Guggenheim lowered the firm’s price target on Insmed (INSM) to $201 from $205 and keeps a Buy rating on the shares.
Insmed price target raised to $204 from $198 at Roth Capital
Roth Capital raised the firm’s price target on Insmed (INSM) to $204 from $198 and keeps a Buy rating on the shares, noting that Brinsupri sales of $400.1M in Q3…
Insmed Earnings Call Transcript: Q3 2026
Q3 revenue growth lifted FY 2026 guidance for both commercial products, while liquidity and the BRINSUPRI trajectory support expected cash flow positivity in 2027. Pipeline trials and potential label expansions remain major growth catalysts.
Insmed Quarterly report: Q3 2026
Insmed has published its Q3 2026 quarterly earnings report on October 29, 2026.
Insmed Earnings release: Q3 2026
Insmed released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Insmed Slides: Q3 2026
Insmed has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
Insmed reports Q3 EPS (46c), consensus (38c)
Reports Q3 revenue $524.4 M, consensus $499.48M. “Q3 marked another period of meaningful progress, defined by commercial momentum, regulatory achievements, and advancement across our diversified pipel...
Insmed updates 2026 outlook
The Company raised 2026 revenue guidance for BRINSUPRI to $1.35B-$1.4B from $1.25B-$1.4B. Raised 2026 revenue view for ARIKAYCE to $460M-$470M from $450M-$470M. Continues to anticipate peak revenues f...
Insmed price target lowered to $154 from $195 at Mizuho
Mizuho lowered the firm’s price target on Insmed (INSM) to $154 from $195 and keeps an Outperform rating on the shares.
Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update
—Total Company Revenues of $524.4 Million for the Third Quarter of 2026— —BRINSUPRI ® (brensocatib) Revenues of $400.1 Million for the Third Quarter of 2026, Reflecting 29% Growth Over the Second Qua...

